Mbody Ai Shares Decline Amid Mixed Market Movements

On Friday, the 23rd of November, shares of Mbody Ai (MBAI) fell by 6.82 % during a 24‑hour trading window that closed at 10:24 PM Central Europe time. At the close, a single Mbody Ai share was priced at approximately USD 2.06 on major exchanges. The company’s market capitalisation stood at USD 33.7 million, and trading volume for the last 24 hours was about USD 34.6 thousand. The 200‑day simple moving average remains near USD 9.47, while the 52‑week high of USD 27.44 was recorded on 26 January 2026. The 52‑week low of USD 2.04 was reached on 22 October 2026.

Context from Peer Performance

  • Bos Better On‑line (BOSC) The stock advanced 0.7 % to USD 4.34. Its market cap is USD 30.5 million and the price‑to‑earnings ratio is 8.25.

  • Freightos (CRGO) Freightos shares rose 0.4 % to USD 0.74. The company’s market cap is USD 39.6 million. Analyst sentiment has been mixed: Freedom Broker lowered its target price, citing limited upside, while Weiss Ratings downgraded from a higher sell to a lower sell. Recent earnings exceeded consensus, with a modest profit per share and revenue above expectations, yet profitability remains negative, reflected in a negative return on equity and a low net margin. The company maintains a conservative capital structure, low debt‑to‑equity, and healthy liquidity. Institutional interest persists, highlighted by a recent stake purchase from a prominent investment firm.

  • Nasus Pharma (NSRX) Shares dropped 5.56 % to USD 3.49, with a market cap of USD 37.3 million.

  • Abra Information Technologie (ABRA.TA) Shares fell 1.19 % to ILS 3.58. The company’s market cap is ILS 114.8 million, and the price‑to‑earnings ratio is 27.38.

  • Shelfie‑tech (SHLFF) The stock remained flat at USD 1.00, with a market cap of USD 24 million.

About Mbody Ai

Mbody Ai is a subsidiary of Check Cap Ltd., a health‑care equipment and supply company headquartered in Isfiya, Israel. Check Cap specialises in the development and manufacture of medical diagnostic equipment. Its flagship product is a non‑invasive device capable of detecting rectal polyps. The system ingests a tiny sonar‑like capsule, transmits data to a wrist‑worn accessory, and generates a three‑dimensional reconstructed image of the colon. Further information about the company’s products and services can be found on its website at www.check‑cap.com . Mbody Ai’s shares are listed on the Nasdaq stock exchange and the company went public on 19 February 2015.

This article provides an overview of Mbody Ai’s recent trading activity and situates the performance within the broader context of peer companies in the sector.